Need for Continued Product Innovation in the Growing U.S Diabetes Market.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47918) has announced the addition of Frost & Sullivan's new report: U.S. Diabetes Pipeline Outlook to their offering. This research service covers the pharmaceutical industry development pipeline for diabetes mellitus diabetes mellitus Disorder of insufficient production of or reduced sensitivity to insulin. Insulin, synthesized in the islets of Langerhans (see Langerhans, islets of), is necessary to metabolize glucose. In diabetes, blood sugar levels increase (hyperglycemia). in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , with 2005 as the base year. Included are both the products projected to enter the market by the end of the forecast coverage period in 2012, as well as products entering the market in 2005 that correspond to the in-depth discussion drug classes. The focus of this piece is on pipeline technology developments and has greater focus on: GLP-1 Agonists, DPP-IV Inhibitors; PPAR PPAR Peroxisome Proliferator Activated Receptor PPAR Physical Partitions Modulators; and Pulmonary Insulin. Also discussed are pipeline developments in other areas of oral antidiabetic drugs Antidiabetic Drugs Definition Antidiabetic drugs are medicines that help control blood sugar levels in people with diabetes mellitus (sugar diabetes). , injectables, and insulins other than pulmonary. Product Analysis charts are included for those products in Phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the . The following technologies are covered in this research: * GLP-1 agonists * DPP-IV inhibitors * Pulmonary insulin * PPAR modulators * Other pipeline efforts Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research: * Pharmaceuticals * Cardiology cardiology Medical specialty dealing with heart diseases and disorders. It began with the 1749 publication by Jean Baptiste de Sénac of contemporary knowledge of the heart. Diagnostic methods improved in the 19th century, and in 1905 the electrocardiograph was invented. * Biotechnology * Diabetes 1 EXECUTIVE SUMMARY * Executive Summary * Introduction 2 MARKET INTRODUCTION * Research Scope and Methodology * Scope and Segmentation * Research Methodology * Diabetes Overview * Introduction * Types of Diabetes * Prevalence * Incidence * Current Treatment * Pipeline Competitive Analysis * Introduction * Key Pipeline Companies * Areas of Opportunity * 3 GLP-1 AGONISTS * Introduction * GLP-1 Agonist agonist /ag·o·nist/ (ag´ah-nist) 1. one involved in a struggle or competition. 2. agonistic muscle. 3. Dynamics * GLP-1 Agonists Pipeline Analysis * Byetta - Amylin & Eli Lilly Eli Lilly can refer to:
* GLP-1 Agonist Pipeline * 4 PULMONARY INSULIN * Introduction * Pulmonary Insulin Dynamics * Pulmonary Insulin Analysis * Exubera - Pfizer & Nektar * Pulmonary Insulin Pipeline 5 DPP-IV INHIBITORS * Introduction * DPP-IV Dynamics * DPP-IV Pipeline Analysis * Pipeline Analysis * 6 PPAR MODULATORS * Introduction * PPAR Dynamics * PPAR Pipeline Analysis * PPAR Pipeline * Discontinued PPAR Modulators * 7 OTHER PIPELINE EFFORTS * Introduction * Other Development Efforts * Pipeline Overviews * Other Insulin Pipeline * Other OAD Pipeline * Other IAD (Integrated Access Device) A device that multiplexes a variety of communications technologies in the customer's premises onto a single telephone line for transmission to the carrier. It also demultiplexes the incoming streams into their respective channels. Pipeline * 8 APPENDIX * Decision Support Databases * Incidence of Diabetes * Prevalence of Diabetes * Diabetes Prevalence as a Percentage of Total Population * Diabetes Foot Ulcer Prevalence as a Percentage of Total Population * Total Population List of Figures For more information visit http://www.researchandmarkets.com/reports/c47918 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion